Nox Peptides is a Canadian-based supplier of research compounds providing peptide products for laboratory and scientific research purposes.
Originally published via Source Article.
Category: News
News
-
Nox Peptides Announces Launch of BPC-157 Research Product and Resources for Canadian Research Market
Nox Peptides is a Canadian-based supplier of research compounds providing peptide products for laboratory and scientific research purposes.
Originally published via Source Article.
-
Nox Peptides Announces Launch of BPC-157 Research Product and Resources for Canadian Research Market
Nox Peptides is a Canadian-based supplier of research compounds providing peptide products for laboratory and scientific research purposes.
Originally published via Source Article.
-
Nox Peptides Announces Launch of BPC-157 Research Product and Resources for Canadian Research Market
Nox Peptides is a Canadian-based supplier of research compounds providing peptide products for laboratory and scientific research purposes.
Originally published via Source Article.
-
Nox Peptides Announces Launch of BPC-157 Research Product and Resources for Canadian Research Market
Nox Peptides is a Canadian-based supplier of research compounds providing peptide products for laboratory and scientific research purposes.
Originally published via Source Article.
-
DIAGNOS Provides an Update on Stock Warrants
BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.
Originally published via Source Article.
-
DIAGNOS fait le point sur les bons de souscription en actions
BROSSARD, Québec, 06 oct. 2026 (GLOBE NEWSWIRE) — Diagnos inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK, OTCQB : DGNOF, FWB : 4D4A), une entreprise dédiée à la détection précoce de maladies critiques de l’œil en utilisant des techniques en intelligence artificielle (IA), fournit une mise à jour concernant les bons de souscription en actions exercés et échus au cours des deux derniers mois (la « Période ») ainsi que le nombre présentement en circulation.
Originally published via Source Article.
-
DIAGNOS Provides an Update on Stock Warrants
BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.
Originally published via Source Article.
-
DIAGNOS fait le point sur les bons de souscription en actions
BROSSARD, Québec, 06 oct. 2026 (GLOBE NEWSWIRE) — Diagnos inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK, OTCQB : DGNOF, FWB : 4D4A), une entreprise dédiée à la détection précoce de maladies critiques de l’œil en utilisant des techniques en intelligence artificielle (IA), fournit une mise à jour concernant les bons de souscription en actions exercés et échus au cours des deux derniers mois (la « Période ») ainsi que le nombre présentement en circulation.
Originally published via Source Article.
-
DIAGNOS Provides an Update on Stock Warrants
BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.
Originally published via Source Article.